Semaglutide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 7 days (165 to 184 hours) Peak concentration: 1 to 3 days after injection Recommended timing approach: Most flexible of all GLP-1 formulations due to the long half-life
Safety, Quality & Compliance Safety and quality are foundational to every compounded medication prepared at Compounding Pharmacy of America
Turton MD, OShea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al
Weight loss injections also cause the body to digest food more slowly, which can further stave off hunger and result in increased satiety
[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
